Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, double blind, randomised, placebo controlled study to assess the efficacy and safety of a single treatment of Clostridium botulinum toxin type A to improve the appearance of moderate to severe glabellar lines.

Next Previous
Trial Profile

A phase III, double blind, randomised, placebo controlled study to assess the efficacy and safety of a single treatment of Clostridium botulinum toxin type A to improve the appearance of moderate to severe glabellar lines.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Therapeutic Use
  • Sponsors Ipsen Limited

Most Recent Events

  • 31 May 2022 According to a Galderma media release, Pooled data from two phase III studies (NCT02353871 and NCT02493946) will be presented at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022.
  • 10 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 24 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top